GALDERMA
11.5.2021 09:02:07 CEST | Business Wire | Press release
Galderma has expanded its consumer care portfolio in Switzerland, where the global dermatology company originated and is headquartered. The expansion offers consumers more options for their dermatology needs. The move includes the introduction of the dermatologist-recommended CETAPHIL® line for sensitive skin, as well as the expansion of the DAYLONG® brand for sun protection.
CETAPHIL is now available in Switzerland
CETAPHIL, the sensitive skincare line recommended by dermatologists worldwide, is now available in Switzerland, exclusively in pharmacies and drugstores. The entry of the CETAPHIL range into the dermo-cosmetic market means consumers now have more choice of topical skincare for sensitive skin.
Swiss consumers can now purchase the core range of CETAPHIL moisturizing creams, moisturizing lotion and gentle skin cleanser. Additionally, the CETAPHIL PRO range for special skin conditions completes the CETAPHIL portfolio. The brand enters the dermo-cosmetic market as a complementary addition to medicine products.
DAYLONG brings new packaging and product to the market
Galderma’s DAYLONG range, a market leader in sun protection in Switzerland, has expanded just in time for May, which is Skin Cancer Awareness Month.
DAYLONG Face Sun to Go Lotion and Stick is practical to carry and easy to apply, offering SPF 50+ for strong protection against UVA, UVB and IR rays.
The whole DAYLONG portfolio also gets a fresh, youthful new look. DAYLONG Sensitive and DAYLONG Sport – product ranges with a proven track record in sun protection – can now be found in a modern clear packaging design, developed in collaboration with Swiss consumers.
"Galderma has been caring for the sensitive skin of millions of people worldwide, and we are excited to expand our offering in Switzerland, our home country.
|
About CETAPHIL
CETAPHIL was developed by a leading pharmacist more than 70 years ago as a gentle, yet powerful formula to clean without stripping and moisturize without clogging. CETAPHIL is the #1 dermatologist-recommended in Germany and the #1 dermatologist-recommended facial skincare brand in the U.S. and is now available in Switzerland. New additions to the brand are regularly developed with the help of leading global skincare experts, providing innovative skincare technologies for sensitive skin that help restore, protect, and maintain skin health every day.
About DAYLONG
Synonymous with Swiss values of continuous research and high-quality, the DAYLONG range is one of the market leaders for sun protection in Switzerland. Since 1993, scientists and experts have worked continuously to develop existing products and is now focused on enhancing their sustainability.
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com
CETAPHIL® is a registered trademark of Galderma Holding AG. Daylong® is a registered trademark of Galderma SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005086/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 14:00:00 CEST | Press release
Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION. Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 202
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 14:00:00 CEST | Press release
New indication in the European Union and the UK offers alternative method of screening especially for women who are not currently participating Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25%
Cover Genius Raises USD $100M Backed by Vista Credit Partners, Reaching USD $1.9 Billion Valuation as it Advances AI-First Platform and Global Expansion14.7.2026 14:00:00 CEST | Press release
Accelerating the AI roadmap and next era of embedded protection Cover Genius, the global infrastructure for embedded protection, today announced a USD $100M capital raise, backed by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on enterprise software. The raise values the business at USD $1.9 billion, advancing a new chapter for the company. Cover Genius operates a B2B2C embedded protection platform that connects 200+ partners with 50+ global insurance carriers to protect over 70 million end customers at the point of sale across travel, retail, ticketing and logistics. Unlike traditional insurers, Cover Genius dynamically adapts product design, pricing, and presentation in real time to match each merchant's unique customer journey and geography mix. “We’ve spent more than a decade building the trust layer the world’s largest digital companies rely on to protect their customers. Today’s raise is about broadening possibilities: movin
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 14:00:00 CEST | Press release
New Titles Expand on Landmark Work to Showcase How GIS Drives Better Decisions Across Water and Land Management Esri will debut the Power of Where Collection at the 2026 Esri User Conference. The collection builds on the 2024 book The Power of Where by Jack Dangermond, extending its ideas into real-world GIS applications. New titles in the collection highlight GIS uses in water forecasting, land records, infrastructure planning, and economic development. The series demonstrates how spatial analysis helps organizations address challenges including sustainability, climate resilience, and governance. Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world a
Esri Introduces ArcGIS for ServiceNow, Bringing Location Intelligence into Everyday Enterprise Workflows14.7.2026 14:00:00 CEST | Press release
New Integration Connects Platforms, Enabling Real-Time Mapping Directly Within Existing Systems Esri is launching ArcGIS for ServiceNow, an integration that connects ServiceNow, the AI control tower for business reinvention, with ArcGIS, bringing location intelligence into everyday enterprise workflows. The solution supports organizations across commercial, government, health care, utilities, energy, telecom, and other sectors. Users can visualize incidents, assets, work orders, facilities, and other business data on maps in real time within ServiceNow or ArcGIS, improving decision-making and operational efficiency. The integration eliminates data duplication by enabling seamless data sharing between systems, bridging business records with geographic context. ArcGIS for ServiceNow will debut in beta shortly after Esri User Conference. Esri, the global leader in geographic information system (GIS) technology, has announced ArcGIS for ServiceNow, connecting the two platforms for the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom